CGRP mitigates myocardial ischemia-reperfusion injury by attenuating ferroptosis through the inhibition of MAMs and mitochondrial division.

Calcitonin gene-related peptide (CGRP) plays a central mechanistic role in migraine and is an established drug target. However, it remains unclear whether peripheral plasma CGRP levels meaningfully reflect disease activity. We investigated whether circulating plasma CGRP differs between individuals with migraine and healthy controls and whether concentrations vary across migraine subtypes, clinical status, and preventive treatment use. This cross-sectional observational study enrolled adults (≥18 years) with migraine with aura, migraine without aura, or chronic migraine primarily from specialized care. Healthy controls without personal or first-degree family history of primary headache disorders were mainly recruited through web-based advertisement. Venous blood was obtained by antecubital phlebotomy, and plasma CGRP was quantified in duplicate using a validated high-affinity radioimmunoassay. Controls were matched 1:4 to participants with migraine on age, sex, body mass index, and storage duration. The primary outcome was between-group difference in plasma CGRP concentrations. Group comparisons were performed using Mann-Whitney U tests. Regression models were performed to assess associations with clinical variables. A total of 588 participants with migraine and 147 matched controls were analyzed (mean age 43.1 ± 11.9 vs 41.5 ± 11.5 years; 88.8% vs 85.7% female). The median (interquartile range) plasma CGRP concentrations were lower in participants with migraine compared with controls (125 [68-173] vs 151 [118-199] pmol/L; p < 0.001). Subgroup analyses revealed no significant differences across subtypes (episodic vs chronic, with aura vs without aura), ictal vs interictal status, or preventive medication use (all p > 0.05). Sensitivity analyses restricted to headache-free participants confirmed the principal findings, demonstrating lower plasma CGRP concentrations across all migraine subgroups compared with controls (all p < 0.001). Multivariable models identified no clinical predictors of plasma CGRP levels. Sample storage duration did not correlate with measured levels (Spearman ρ = -0.032; p = 0.37). Plasma CGRP concentrations were modestly lower in migraine and did not vary by clinical subtype or disease state. These findings challenge the assumption that migraine is characterized by elevated circulating CGRP and suggest limited utility of plasma CGRP as a disease biomarker.

Electrospun PCL/PVA core-sheath nanofibres enabling staged antibiotic and peptide delivery for diabetic foot ulcer dressings.

Respiratory diseases, including bacterial pneumonia, viral infections and allergic asthma, are leading causes of hospitalization, yet current therapies often fall short. The lower airways are densely innervated by pain-transmitting sensory neurons (nociceptors) that arise from the nodose-jugular ganglia of the vagus nerve, with additional contributions from the spinal dorsal root ganglia. Converging evidence indicates that reciprocal neuroimmune signalling between lung-innervating sensory neurons and immune cells lies at the centre of pulmonary defence, inflammation and tissue repair. Among several immunomodulatory neuropeptides, calcitonin gene-related peptide (CGRP), released by activated TRPV1-positive nociceptors, has context-dependent functions. CGRP supports tissue protection and repair by shaping macrophage and neutrophil activation states, yet these same actions can exacerbate pathology during bacterial infection. In allergic asthma, pulmonary neuroendocrine cells act as early epithelial sentinels that amplify type 2 immunity and help todefine state-dependent effects of CGRP as well as other neuropeptides, including vasoactive intestinal peptide (VIP), neuromedin U (NMU) and substance P (SP). An updated framework that accounts for phase-specific and context-specific neuromodulation could enable new therapeutic strategies, including targeted inhibition or modulation of defined pathways to preserve essential reflexes while meaningfully altering disease trajectories and outcomes. Incorporating the neural state and exposure history will be critical for developing disease-modifying therapies informed by pulmonary neuroimmunology.

Perineural invasion in head and neck squamous cell carcinoma: Neuro-immune mechanisms driving immunotherapy resistance and emerging therapeutic strategies.

Background: Migraine is a disabling neurovascular disorder that may evolve from episodic to chronic forms, often complicated by medication-overuse headache (MOH). It generates substantial healthcare expenditures and indirect societal costs. Pharmacological constraints and resistance to acute therapies contribute to the development of MOH and increase the need for preventive treatments such as onabotulinumtoxin A (BoNT/A) and monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway. Objective: This pharmacoepidemiology retrospective study aimed to evaluate real-world prescription patterns of BoNT/A and anti-CGRP/R mAbs in an Italian regional setting and to compare current data (2023–2024) with previously observed patterns (2020–2022) before the integration of pharmacists as outpost in migraine man-agement. Methods: Anonymized data were obtained from the regional drug reimbursement and prescription database. Results: A total of 9,012 and 9,705 prescriptions were recorded in 2023 and 2024, respectively, indicating an increasing trend in the use of innovative preventive therapies. A gradual increase in the use of eptinezumab and BoNT/A appears to be associated with regional organizational measures aimed at improving access to care, adherence to clinical guidelines, and integrated management across healthcare levels. Conclusion: Therapeutic appropriateness is far from reaching the gold standard and an increasing role of pharmacists could improve clinical outcomes.

The potential to mitigate pain by targeting a single receptor while simultaneously modulating peripheral and spinal circuits, offers an exciting nonopioid therapeutic strategy. Neurotensin receptor type 2 (NTSR2) is a promising yet underexplored pathway for nonopioid analgesia. The authors investigated the antinociceptive effects of NTSR2 activation and its mechanisms in rodent models of perioperative and chronic pain. Using NT79, a selective NTSR2 agonist, the authors assessed pain behaviors in male and female rats and mice. Animals were randomly assigned to receive saline (control) or NT79 at multiple doses. Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9)-mediated NTSR2 knockdown and pharmacologic inhibition of γ-aminobutyric acid (GABA) receptors were used to dissect NTSR2-dependent mechanisms. Dorsal root ganglion (DRG) calcium imaging, whole cell patch clamp electrophysiology, and spinal neurotransmitter assays evaluated the modulation of voltage-gated calcium channels and γ-aminobutyric acid-mediated (GABAergic) signaling. Intrathecal NT79 produced robust, dose-dependent antinociception across pain models, species, and sexes, an effect abolished by NTSR2 knockdown. NT79 reduced high-voltage-activated calcium currents in DRG neurons, indicating a presynaptic inhibitory mechanism. In the spinal cord, NT79 enhanced GABA release and suppressed calcitonin gene-related peptide (CGRP) release. Pharmacologic blockade of GABA receptors partially reversed NT79's antinociceptive effects, as did NTSR2 knockdown in GABAergic neurons, supporting a central GABAergic mechanism in addition to the effect on central DRG terminals. Taken together, these results demonstrate that NTSR2 activation produces sustained antinociception via dual-site modulation: inhibition of peripheral voltage-gated calcium channels and enhancement of spinal GABAergic signaling. These findings identify a novel, nonopioid mechanism of analgesia and support NTSR2 as a therapeutic target for chronic pain.

This narrative review summarizes evidence implicating a role for the hypothalamus in the prodrome phase of a migraine attack. Prodrome is the earliest phase of the migraine attack. Understanding the migraine prodrome could lead to a better description of how migraine attacks are initiated and identification of targets for acute and preventive migraine treatment. The hypothalamus has been implicated in migraine prodrome via (1) localization of common prodrome symptoms to the hypothalamus; (2) identification of neurotransmitters, peptides, and hormones important in migraine pathophysiology for which the hypothalamus influences their production or release; and (3) brain neuroimaging studies identifying changes in hypothalamic activity and functional connectivity during the prodrome and preheadache phases of the migraine attack. For this narrative review, PubMed was searched for relevant English language articles using the terms "hypothalamus, prodrome," "hypothalamus, premonitory," "hypothalamus, migraine," "migraine, prodrome," and "migraine, premonitory." The PubMed search was performed on October 29, 2025. Full articles were chosen for review based on their relevance to the three areas defined just above: symptom localization, neuropeptide/neurotransmitter release, and brain imaging. Those with migraine commonly, and often consistently, experience prodrome symptoms, including hypersensitivities to visual and auditory stimuli, neck pain, fatigue, sleep-wake disturbances, changes in appetite, mood changes, and alterations in thermoregulation perception. Many of these symptoms can be localized to functions of hypothalamic subregions and nuclei. Several neuropeptides, neurotransmitters, and hormones that contribute to prodrome and other migraine attack symptoms, including calcitonin gene-related peptide, dopamine, orexins, and pituitary adenylate cyclase-activating polypeptide, are either produced by the hypothalamus or their release is mediated by the hypothalamus. Functional neuroimaging studies of spontaneous and triggered migraine attacks have identified increased hypothalamic activity and altered hypothalamic functional connectivity before migraine headache onset, including during the prodrome. There is compelling evidence that the hypothalamus plays a role in the migraine prodrome and likely in migraine attack initiation. This is supported by many migraine prodrome symptoms localizing to hypothalamic function and functional neuroimaging studies demonstrating increased activity and altered connectivity of the hypothalamus during the prodrome phase. Further evidence and research are required to understand the hypothalamus' contribution relative to other brain regions.

Skin-mimetic bilayer hydrogel enhances spatiotemporal coordination of neuro-immune-vascular interactions to accelerate diabetic wound healing.

Photobiomodulation Therapy for Peripheral Neuropathy in Diabetic and Cancer Patients: A Narrative Review.

To investigate the mechanism by which electroacupuncture (EA) at "Zusanli" (ST36) ameliorates the impairment of feeding behavior and gastric vagal afferent signaling induced by short-term high-fat diet (HFD) exposure. The study comprised two parts. In part 1, 42 SPF male C57BL/6J mice were randomly divided into a normal diet (ND) group (n=14) and an HFD group (n=28). After 4 weeks, HFD-fed mice were subdivided into an HFD group and an EA group (n=14 each). The EA group received EA at bilateral "Zusanli" (ST36). Stimulation parameters were:2 mA, 2 Hz/15 Hz, 20 min/session, once daily, 6 sessions/week for 2 consecutive weeks. Body weight was recorded weekly. After the intervention, 24 h food intake was measured. Liver wet weight, inguinal white adipose tissue (iWAT) wet weight, and epididymal white adipose tissue (eWAT) wet weight were recorded. Gastric emptying rate was assessed using the phenol red meal test. Serum cholecystokinin (CCK) content was measured by ELISA. Protein expressions of protein gene product 9.5 (PGP9.5) and calcitonin gene-related peptide (CGRP) in the gastric antrum were evaluated by Western blot. The co-expression density index of PGP9.5 and CGRP in the gastric antrum and c-Fos expression levels in the nodose ganglion (NG) were detected by immunofluorescence staining. In part 2, another 32 SPF male C57BL/6J mice were fed an HFD for 4 weeks and then randomly divided into 4 groups (n=8 each):sham operation group, sham + EA group, vagotomy (resection of the gastric vagal branches) group, and vagotomy + EA group. The acupoint and intervention parameters were the same as above. Body weight, 24 h food intake, liver wet weight, iWAT wet weight, eWAT wet weight, the co-expression of PGP9.5 and CGRP in the gastric antrum, and the number of c-Fos positive neurons in the NG were measured. Compared to the ND group, 4-week HFD feeding increased body weight, liver wet weight, and adipose tissue (iWAT and eWAT) wet weights, while decreased gastric emptying rate and serum CCK levels(P<0.05). The relative protein expressions of both PGP9.5 and CGRP in the gastric antrum were down-regulated(P<0.05). Meanwhile, the co-expression density index of PGP9.5 and CGRP in the gastric antrum was reduced(P<0.05). The number of c-Fos positive neurons in the NG decreased in HFD-fed mice(P<0.05). Compared to the HFD group, EA treatment reduced body weight, 24 h food intake, liver wet weight, and adipose tissue (iWAT and eWAT) wet weights(P<0.05). EA also increased gastric emptying rate and serum CCK levels(P<0.05). Moreover, EA up-regulated the relative protein expressions of PGP9.5 and CGRP as well as their co-expression density index in the gastric antrum(P<0.05). Finally, EA increased the number of c-Fos positive neurons in the NG(P<0.05). In the vagotomy experiment, compared with the sham operation group, the sham{L-End} +{L-End} EA group showed a significant decrease in body weight, food intake, liver wet weight, adipose tissue wet weight (P<0.05). After gastric branch vagotomy, however, the regulatory effects of EA on body weight, food intake, liver wet weight, and other indicators were weakened. Similarly, after surgery EA did not exert a significant modulatory effect on the co-expression level of PGP9.5 and CGRP in the gastric antrum or on the expression of c-Fos-positive neurons in the NG. Short-term HFD leads to desensitization of gastric vagal afferent signaling, manifested as impairment of local gastric vagal sensory nerves and a decrease in the number of activated neurons in the NG. EA can suppress food intake by repairing gastric vagal afferent signaling.

To investigate the mechanism of electroacupuncture (EA) at sensitized "Sanyinjiao" (SP6) in improving primary dysmenorrhea (PDM), with a focus on the role of Piezo1 protein in EA effects. Sixty female rats were randomly divided into a blank group (n=10) and a model establishment group (n=50). Mechanical pain thresholds at the left SP6 acupoint were measured using a von Frey electronic algometer. According to the change rate of mechanical pain threshold, the model establishment group was further divided into model high-sensitization group, model low-sensitization group, EA high-sensitization group, and EA low-sensitization group (n=10 each). The PDM rat model was established by combined injection of estradiol benzoate and oxytocin. The two EA groups received EA at SP6 (50 Hz, dense wave, 20 min/d) for 5 consecutive days.Writhing responses were recorded to evaluate abdominal pain severity;uterine blood flow was observed by laser speckle imaging;uterine histopathology was examined by HE staining;mast cell degranulation rate at the SP6 region was detected by toluidine blue staining;ultrastructural changes of uterine tissue were observed by transmission electron microscopy;levels of prostaglandin E2 (PGE2), prostaglandin F2α (PGF2α) in serum and uterine homogenate, and serum tumor necrosis factor-α (TNF-α) were measured by ELISA;protein expressions of Piezo1, calcitonin gene-related peptide (CGRP), and Tryptase in the SP6 region, as well as Piezo1 in the uterus, were detected by Western blot;immunofluorescence was used to detect CGRP and Tryptase expressions at SP6;RT-qPCR was performed to measure mRNA expressions of Piezo1 and cyclooxygenase-2 (COX-2) in the uterus. Compared with the blank group, the model high-sensitization and model low-sensitization groups showed increased writhing times, writhing scores and writhing latencies (P<0.01), decreased uterine blood perfusion (P<0.01), elevated uterine pathological scores (P<0.01), and increased mast cell degranulation rate (P<0.01). Serum and uterine PGF2α contents, serum TNF-α content and PGF2α/PGE2 ratio were significantly increased (P<0.01), while serum and uterine PGE2 contents were significantly decreased (P<0.01). Protein expressions of Piezo1, CGRP, Tryptase, and positive expressions of CGRP and Tryptase at the acupoint, mRNA and protein expressions of Piezo1, and COX-2 mRNA in the uterus were up-regulated (P<0.01), accompanied by ultrastructural damage in uterine tissue. Compared with the corresponding model groups, the writhing latencies were increased further, and the other indicators mentioned above were significantly reversed in the two EA groups (P<0.01, P<0.05). Moreover, the EA high-sensitization group exhibited more obvious improvements than the EA low-sensitization group (P<0.01). EA at SP6 with different sensitization states effectively alleviates pain in PDM rats, with a better effect in the high-sensitization state. The mechanism is dependent on acupoint sensitization, which may involve regulating Piezo1 expression at the acupoint, inhibiting mast cell degranulation and neurogenic inflammation, and down-regulating the Piezo1/COX-2/PGs pathway in the uterus to reduce inflammatory factor release, thereby producing analgesic effects.

A multi-model genome-wide association study identifies genetic variants underlying resistance to Largemouth Bass Ranavirus (LMBV) in Micropterus salmoides.

Migraine attacks can be provoked in people with underlying primary headache disorders by multiple peripheral mechanisms suggesting the possible convergence of trigeminal nociceptive inputs onto a common, unknown central circuit. As calcitonin gene-related peptide (CGRP) expressing cells in the parabrachial nucleus (PBN) have been implicated in nociplastic pains, we hypothesized that (a) PBN CGRP-expressing neurons and their projections to the central amygdala (CeA) may be an essential central relay of multiple peripheral inputs promoting injury-free migraine headache and (b) this pathway may prioritize threat from activation of cranial afferents over other nociceptive inputs. Periorbital cutaneous allodynia (CA) was determined following supradural application of a cocktail of inflammatory mediators (IM), CGRP or pituitary adenylate cyclase-activating polypeptide (PACAP), or systemic administration of nitroglycerin (NTG) in CalcaCre or wild-type mice. Decreased rearing and photophobia were respectively evaluated as measures of ongoing headache and light-evoked migraine-like pain. Phosphorylation of extracellular signal-regulated kinases (pERK) was evaluated to assess regional neuronal activation. Compared with vehicle, supradural IM increased pERK in the trigeminal nucleus caudalis and PBN, but not in the paraventricular thalamus. Chemogenetic activation (Gq-DREADD) of PBN CGRP neurons elicited CA and photophobia while decreasing rearing. Lesioning of PBN neurons with ibotenic acid suppressed CA produced by supradural IM. Chemogenetic silencing (Gi-DREADD) or expression of tetanus toxin (TeNT) in PBN Calca neurons to prevent neurotransmitter release also inhibited CA elicited by supradural IM, CGRP, PACAP or systemic NTG. CRISPR/Cas9 editing of CeA receptor-associated membrane protein-1 (Ramp1) prevented IM-induced migraine-like symptoms revealing CGRP/CGRP-receptor activation from PBN→CeA projections. In contrast, PBN lesions, chemogenetic manipulation, and TeNT expression in PBN Calca cells and CeA Ramp1 CRISPR/Cas9 editing did not affect acute pain responses induced by hind paw IM injection, intraperitoneal acetic acid, or acute nociceptive behaviors from IM stimulation of the maxillary (V2) and mandibular (V3) branches of the trigeminal nerve. These data reveal a central pathway composed of PBN Calca neurons and CeA CGRP receptor signaling that is both sufficient to elicit migraine-like pain in naive mice and necessary to promote migraine-like pain following activation of the ophthalmic (V1) branch of the trigeminal nerve. Importantly, this pathway is essential for acute pain arising from V1 trigeminal, but dispensable for acute stimuli from other nociceptive afferents. The prioritization of V1 acute nociception suggests evolutionary importance for detecting threats to the head to promote survival through advantageous behaviors such as defensive coping observed in migraine.

CGRP-uric acid axis in migraine: A redox-inflammatory framework linking neurovascular signaling and metabolic regulation.

Advancing our understanding of astrocyte-mediated neurochemical communication and the role that calcium plays in astrocyte function may ultimately enable the development of strategies for diagnosing, treating, and preventing conditions that involve astrocyte dysfunction, including calcitonin gene-related peptide (CGRP)-based neurovascular disorders. We investigated the utility of intracellular calcium concentration and metabolic changes as potential indicators of astrocyte dysfunction. We used CGRP to induce cellular dysfunction in CTX-TNA2 astrocytes and examined the relationship between astrocyte dysfunction and intracellular calcium levels using inductively coupled plasma-optical emission spectrometry. In addition, we compared the metabolic and neurochemical profiles of untreated (control) astrocytes with those of CGRP- and CaCl2-treated astrocytes. Higher intracellular calcium concentrations were observed in the CGRP-treated astrocytes. Glucose metabolites exhibited chemical shifts in the control and CaCl2-treated astrocytes but were less evident in CGRP-treated astrocytes, suggesting potential alterations in glucose metabolism. The CGRP-treated astrocytes also had significantly lower levels of creatine (Cr), the glutamate-glutamine complex (Glx), and myo-inositol than the control astrocytes. The Cr and myo-inositol levels were significantly higher in the CaCl2-treated astrocytes than in the control astrocytes. Our findings suggest that monitoring the intracellular calcium concentration and metabolic profile can be a valuable approach for detecting early astrocyte dysfunction. The metabolic and neurochemical changes induced by CGRP highlight the potential of astrocyte-targeted strategies for mitigating CGRP-related neurovascular disorders.

This study aimed to systematically summarize and pool the available evidence on the risk of incident hypertension associated with calcitonin gene-related peptide (CGRP)-targeted therapies. CGRP-targeted therapies have emerged as effective preventive treatments for migraine; however, concerns have been raised regarding their potential hypertensive effects. Prior studies have been limited by small sample sizes, inconsistent definitions of hypertension, and incomplete trial inclusion. We systematically searched MEDLINE, Embase, and ClinicalTrials.gov up to September 25, 2024. We included randomized controlled trials comparing CGRP-targeted therapies with placebo or another intervention arm in adult patients with migraine. The primary outcome was incident hypertension as defined by each individual study. Two reviewers independently assessed risk of bias using the Cochrane Risk of Bias 2 tool and rated the certainty of evidence using the Grading of Recommendations Assessment, Development, and Evaluation approach. Eight publications or trial reports, comprising 19 underlying randomized controlled trials, were included. The pooled relative risk (RR) for hypertension with CGRP-targeted therapies versus control was 0.91 (95% confidence interval [CI] 0.58-1.43; I² = 0.0%), indicating no statistically significant increased risk. The certainty of evidence for this outcome was rated as very low. Erenumab showed no significant increase in risk (RR 0.71, 95% CI 0.30-1.70), whereas galcanezumab also showed no statistically significant association (RR 1.14, 95% CI 0.54-2.39). CGRP-targeted therapies were not associated with a statistically significant increase in hypertension risk in patients with migraine, particularly among relatively healthy populations enrolled in short-term randomized controlled trials. However, the certainty of evidence was very low, and possible variation across agents warrants further study. Longer term comparative studies and real-world observational studies with standardized blood pressure monitoring are needed to confirm these findings and better define hypertension risk in higher risk patient subgroups.

Systematic comparison of GTN- and CGRP-induced migraine-like behaviors across sex and strain in mice.

Vitiligo is a chronic autoimmune depigmenting disorder affecting 0.5%-2% of the global population, characterized by bidirectional interplay between psychological stress and disease progression, with accumulating evidence highlighting the central role and translational relevance of the neuro-endocrine-immune-cutaneous axis in its pathogenesis. Epidemiological data indicate over half of patients experience significant psychological stress prior to disease onset, while visible depigmentation markedly elevates the burden of depression and anxiety, establishing a self-amplifying pathogenic loop. Mechanistically, neural crest-derived melanocytes form functional "neuro-pigment units" with intraepidermal nerve endings, enabling bidirectional communication via neuropeptides including calcitonin gene-related peptide (CGRP) and substance P. Dynamic crosstalk among keratinocytes, sensory neurons, and melanocytes integrates neurotrophic and inflammatory signals to tightly regulate melanocyte survival and biological function. Sympathetic activation drives melanocyte injury via norepinephrine-mediated β2-adrenergic receptor signaling, while dopamine metabolites exacerbate apoptosis via the oxidative stress-Akt-Bad axis; context-dependent hypothalamic-pituitary-adrenal axis effects and light-melatonin-circadian clock disruption further promote immune dysregulation and melanocyte loss. Notably, neuromodulatory approaches like transcutaneous auricular vagus nerve stimulation show therapeutic promise by attenuating oxidative stress and limiting pathogenic CD8⁺ T-cell infiltration. These insights have fostered targeted strategies including CGRP receptor antagonists and dual antioxidant-neuroprotective natural compounds. Integrating neuroimmunological modulation with psychological and circadian interventions represents a promising precision medicine framework for vitiligo management.

Migraine is a leading cause of disability worldwide, impairing quality of life and productivity. Preventive therapies aim to reduce attack frequency, severity and the need for acute medications. Oral atogepant (60mg), a calcitonin gene-related peptide (CGRP) receptor antagonist, has recently expanded migraine prevention options. This study evaluated changes in triptan use after atogepant initiation using real-world data. This retrospective observational study used administrative healthcare databases from the Local Health Unit of Modena (Italy). Adults with chronic or high-frequency episodic migraine initiating atogepant between November 2023 and December 2024 were identified. Triptan use and related costs were assessed in the 6 months before and after treatment initiation (index date), measured as dispensed dosage units. Among 95 patients (86% female; mean age 53.5 years), 55 triptan users were included in the analysis. Triptan use decreased in 45 patients (82%), with ≥ 60% reduction in 27 (49%) and complete discontinuation in 10. Median consumption decreased from 76 to 24 dosage units, and mean consumption from 88.1 to 45.2. This reduction was statistically significant (Wilcoxon signed-rank test, p < 0.001). This reduction corresponded to a decrease of €2,591 in triptan-related pharmaceutical expenditure within the study cohort. Atogepant preventive treatment may substantially reduce acute migraine medication use in real-world practice, with potential clinical and economic benefits.